Share Name Share Symbol Market Type Share ISIN Share Description
Ekf Diagnostics LSE:EKF London Ordinary Share GB0031509804 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 17.50p 16.75p 18.50p - - - 14,286.00 10:00:21
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 30.0 -15.8 -8.8 - 81.25

Ekf Diagnostics (EKF) Latest News

More Ekf Diagnostics News
Ekf Diagnostics Takeover Rumours

Ekf Diagnostics (EKF) Share Charts

1 Year Ekf Diagnostics Chart

1 Year Ekf Diagnostics Chart

1 Month Ekf Diagnostics Chart

1 Month Ekf Diagnostics Chart

Intraday Ekf Diagnostics Chart

Intraday Ekf Diagnostics Chart

Ekf Diagnostics (EKF) Discussions and Chat

Ekf Diagnostics Forums and Chat

Date Time Title Posts
24/11/201614:35EKF Diagnostics - Growth by acquisition, expertise and special relationships1,166.00
27/7/201105:35EKF Diagnostics – Growth by acquisition, expert knowledge and special relationsh7.00
25/7/201113:22EKF Diagnostics209.00
13/7/201020:15EFK DIAGNOSTICS6.00

Add a New Thread

Ekf Diagnostics (EKF) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
05/12/2016 16:36:4517.0010,0001,700.00O
05/12/2016 16:35:0517.5033,0005,775.00UT
05/12/2016 16:21:4917.2550,0008,625.00O
05/12/2016 15:14:5117.938,5001,524.42O
View all Ekf Diagnostics trades in real-time

Ekf Diagnostics (EKF) Top Chat Posts

Ekf Diagnostics Daily Update: Ekf Diagnostics is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker EKF. The last closing price for Ekf Diagnostics was 17.50p.
Ekf Diagnostics has a 4 week average price of 17.44p and a 12 week average price of 16.36p.
The 1 year high share price is 18.25p while the 1 year low share price is currently 0p.
There are currently 464,262,781 shares in issue and the average daily traded volume is 185,604 shares. The market capitalisation of Ekf Diagnostics is £81,245,986.68.
interstellar: Az. Sure. And Tesco is a case in point. Lots of people got a surprise when some of their hidden accounting practises came to light. It took a whistle blower to point them out. I'm just trying to point out that headline numbers when expressed in certain ways can be deceiving. The track record so far for EKF is not great despite much promise. Now they are meant to be on firmer ground with a clear sight of the goals (if not the end of the tunnel) but there is a notable absence of activity in the share price going north, or newsflow come to that, to underline these favourable expectations.
andrewbaker: The recent share purchase (see news articles on quotes page) suggests that the company is prospering/will prosper greatly going forward. The weakness of the £ sterling combined with sales in US$ and other currencies is a big boost for many British businesses; and if their core product(s) are improving in sales/prospects too, that's a double bonus. A continuing rise in the EKF share price looks very much on the cards right now and going forward.
wan: An encouraging and upbeat Trading Update today, as well as clarifying that Brexit will have no effect on sales - "the Board notes that it does not anticipate any impact to sales from the forthcoming decoupling of the United Kingdom from the European Union. EKF sales into EU countries are derived entirely from offices within the EU and US, with no such sales made from the UK and therefore global sales are not expected to be impacted."
cisk: With his shareholding and loan to the company I don't think it's over with him at all, in fact I'm surprised he resigned. I'm also surprised with the share price reaction today - i.e. it's gone up. It's very clear there's an awful lot of work to do, both in terms of restoring management credibility and actually making a proper profit. Currently all the share price offers is hope. My fingers have been burnt on this one in the past, I'd rather buy back at a higher price, after tangible evidence of progress on the bottom line is evident.
wan: I am not suggesting that the postponement of the Results by a week is anything to do with the following, it's just food for thought; Some might recall that as reported by EKF, RZ is also currently Chairman and Chief Executive Officer of Lumira Holdings Ltd. But what interested me more was the connected business Lumira Diagnostics Ltd. I further noticed the following job vacancy description, which was posted in December 2015 (no other job listings state that Multi-Sense is a subsidiary of Lumira) - Engineering And Manufacturing Manager in Lumira Diagnostics (UK) Multi-Sense, a subsidiary of Lumira, are a young and energetic company developing revolutionary and flexible assay platform technologies that will transform In Vitro Diagnostic testing and provide next generation healthcare. The company was founded in 2009 and is located at our newly built facility in Stirling. We are looking for a proactive, talented, focused and enthusiastic individual who can make a significant contribution to the continued growth and success of our company. (end) Revolutionary and transforming have big meanings, but are obviously just words at present and there may be no connection and just a typo. RZ is not listed as a director at Multi-Sense, however, his fellow directors at Lumira, Dr David Scott and Dr Jerome Francis Francis Mcaleer, are both directors at Muti-Sense. Very recently, and apparently as a result of growth, Multi-Sense Technologies have posted quite a few vacancies - March 2016: Due to continued growth, we are currently recruiting for a variety of roles as shown below: Multi-Sense and Lumira are still listed as a private independent companies, but that does not mean that that is still the case as Companies House will get updated at the next filing date. I also noticed that the following individual has apparently done some work for Lumira - Richard R. Kelly Rich concentrates on cross-border and domestic M&A representation and corporate fiduciary counseling. He co-heads the firm’s International Practice. Lumira Holdings Ltd in its expatriation to the U.K. and in connection with its private placements and acquisitions of connected health companies. RZ has quite a bit of history and connection with companies/deals in Scotland. Thus it will be interesting to see what materializes, or indeed if there is any connection formed with Lumira and/or multi-Sense.
cisk: Inter, talk is cheap and these guys have been paid handsomely for their efforts - or lack of. Anyone can apologise - indeed I've witnessed this first hand several times from these guys; it will take more than talk to get this share price up.
cisk: all, tbh I would expect the likes of Baines et al to be buying shares in the market at the current level. If they can't announce sales etc then thats the only option to shore up confidence. Assuming they could of course... I'm thoroughly disappointed in this whole episode - after hearing them discuss the tech, pipeline and opportunities at length many times I'm seriously surprised we're where we are. The much-trumpeted sales to Mexico for example have not been announced. Nor do I hold out hope of RZ coming to the rescue at a price anywhere near what we would find appetising. He didn't make a fortune by being generous to shareholders of companies he wants to acquire. Wan, I know you thought 10p was wide of the mark, but if RZ spots an opportunity to buy the whole lot, spin off the molecular division on nasdaq in 6 months and develop the diagnostic side, he'll take it and pay the minimum to do so. And the institutions that bought around 40p if memory serves would probably be glad to get this company off their books at 10p as it's unlikely they could shift any serious volume of stock without collapsing the share price even more from current levels. what the company is actually worth is anyone's guess. Probably what RZ is prepared to pay as so far he looks like the only person who might buy the company.
kestelmill: My hunch is this: -RZ sees this company as his next vehicle -RZ strategy will be as per his normal strategy - become major global Dx player via acquisition -RZ is fairly well aligned with DE/JB on strategy -Hence when DE/JB were challenged by major shareholders they saw RZ chairmanship as a good fall back option -They now have carte blanche to progress, at least for the time being. A bit like when a football club appoints a new manager - they've got a reasonable period to succeed. -Major shareholders will realise this and if it doesn't fit with their investment approach (risk, etc) they will bail out. This is happening now hence share price going down. -I wouldn't be surprised if RZ becomes CEO. It depends on his relationship with JB and how many shares he buys. -All depends on RZ now. Not such a bad horse to back but share price likely to go down before it recovers.
cisk: Morning Wan Agree - Mgt will be judged on next month's update - but as we both know, it takes a long time to gain any sort of traction in diagnostics - in fact anything healthcare related - as my small holding in Deltex will attest to! Very interesting news re: Alere; given the already strong relationship between them and Ron's shareholding in both companies it would not be a surprise. However I'm in it for the long term and believe that the share price can be at multiples of its current level, so personally I wouldn't want to see them taken over at a price anywhere near the current share price. Hopefully patience will be my biggest ally...
totaleclipse: Just to put in a tiny bit more information I heard that Selah sales people were being paid very high commissions per test to incentivize them. Like half! That's kind of excessive dont you think? If the reimbursers discovered that bit of information I would guess they would be less than happy as it suggests the margins are very wide and maybe the reason for the cut. >>Bigman. You spotted a good point. If we focus on the next driver for the EKF share price- i.e. the 6 months results, the sales will be enhanced by just the $0.5m you calculate for April and a further $1.5m for May and June- not sure if that is going to reignite the shares to recover their upward path. Anyone have any views on the 6 month numbers?
Ekf Diagnostics share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:32 V: D:20161206 10:20:23